An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective
Abstract Background Three recent randomized controlled trials demonstrated that, in patients with symptomatic paroxysmal atrial fibrillation (PAF), first-line pulmonary vein isolation with cryoballoon catheter ablation reduces atrial arrhythmia recurrence compared to initial antiarrhythmic drug (AAD...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Health Services Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12913-024-11967-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216357092655104 |
|---|---|
| author | Malte Kuniss Lucy Hillcoat Joe Moss Florian Straube Jason Andrade Oussama Wazni Gian Battista Chierchia Lukas Schwegmann Eleni Ismyrloglou Alicia Sale Stuart Mealing Tom Bromilow Emily Lane Damian Lewis Andreas Goette |
| author_facet | Malte Kuniss Lucy Hillcoat Joe Moss Florian Straube Jason Andrade Oussama Wazni Gian Battista Chierchia Lukas Schwegmann Eleni Ismyrloglou Alicia Sale Stuart Mealing Tom Bromilow Emily Lane Damian Lewis Andreas Goette |
| author_sort | Malte Kuniss |
| collection | DOAJ |
| description | Abstract Background Three recent randomized controlled trials demonstrated that, in patients with symptomatic paroxysmal atrial fibrillation (PAF), first-line pulmonary vein isolation with cryoballoon catheter ablation reduces atrial arrhythmia recurrence compared to initial antiarrhythmic drug (AAD) therapy. This study aimed to evaluate the cost-effectiveness of first-line cryoablation compared to first-line AADs from a German healthcare payer perspective. Methods Individual patient-level data from 703 participants with untreated PAF enrolled into three randomized clinical trials (Cryo-FIRST, STOP AF First and EARLY-AF) were used to derive parameters for the cost-effectiveness model (CEM). The CEM structure consisted of a hybrid decision tree and Markov model. The decision tree (one-year time horizon) informed initial health state allocation in the first cycle of the Markov model (40-year time horizon; three-month cycle length). Health benefits were expressed in quality-adjusted life years (QALYs). Cost inputs were sourced from German diagnosis-related groups and the Institute for the Hospital Remuneration System (InEK). Costs and benefits were discounted at 3% per annum. Results Cryoablation was cost-effective, incurring ~ €200 per patient while offering an increase in QALYs (~ 0.18) over a lifetime. This produced an average incremental cost-effectiveness ratio of ~ €1,000 per QALY gained. Individuals were expected to receive ~ 1.2 ablations over a lifetime, regardless of initial treatment. However, those initially treated with cryoablation as opposed to AADs experience 0.9 fewer re-ablations and a 45% reduction in time spent in AF health states. Conclusion Initial rhythm control with cryoballoon ablation in symptomatic PAF is a cost-effective treatment option in a German healthcare setting. |
| format | Article |
| id | doaj-art-4766e7497ae84ae7b3a3a48fa0750b7f |
| institution | OA Journals |
| issn | 1472-6963 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj-art-4766e7497ae84ae7b3a3a48fa0750b7f2025-08-20T02:08:20ZengBMCBMC Health Services Research1472-69632024-11-0124111310.1186/s12913-024-11967-0An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspectiveMalte Kuniss0Lucy Hillcoat1Joe Moss2Florian Straube3Jason Andrade4Oussama Wazni5Gian Battista Chierchia6Lukas SchwegmannEleni Ismyrloglou7Alicia Sale8Stuart Mealing9Tom Bromilow10Emily Lane11Damian Lewis12Andreas Goette13Kerckhoff Heart CenterYork Health Economics ConsortiumYork Health Economics ConsortiumHeart Center Munich-BogenhausenUniversity of British ColumbiaCleveland ClinicUniversitair Ziekenhuis Brussel and Vrije Universiteit BrusselBakken Research Center B.VMedtronicYork Health Economics ConsortiumYork Health Economics ConsortiumYork Health Economics ConsortiumYork Health Economics Consortium Vincenz HospitalAbstract Background Three recent randomized controlled trials demonstrated that, in patients with symptomatic paroxysmal atrial fibrillation (PAF), first-line pulmonary vein isolation with cryoballoon catheter ablation reduces atrial arrhythmia recurrence compared to initial antiarrhythmic drug (AAD) therapy. This study aimed to evaluate the cost-effectiveness of first-line cryoablation compared to first-line AADs from a German healthcare payer perspective. Methods Individual patient-level data from 703 participants with untreated PAF enrolled into three randomized clinical trials (Cryo-FIRST, STOP AF First and EARLY-AF) were used to derive parameters for the cost-effectiveness model (CEM). The CEM structure consisted of a hybrid decision tree and Markov model. The decision tree (one-year time horizon) informed initial health state allocation in the first cycle of the Markov model (40-year time horizon; three-month cycle length). Health benefits were expressed in quality-adjusted life years (QALYs). Cost inputs were sourced from German diagnosis-related groups and the Institute for the Hospital Remuneration System (InEK). Costs and benefits were discounted at 3% per annum. Results Cryoablation was cost-effective, incurring ~ €200 per patient while offering an increase in QALYs (~ 0.18) over a lifetime. This produced an average incremental cost-effectiveness ratio of ~ €1,000 per QALY gained. Individuals were expected to receive ~ 1.2 ablations over a lifetime, regardless of initial treatment. However, those initially treated with cryoablation as opposed to AADs experience 0.9 fewer re-ablations and a 45% reduction in time spent in AF health states. Conclusion Initial rhythm control with cryoballoon ablation in symptomatic PAF is a cost-effective treatment option in a German healthcare setting.https://doi.org/10.1186/s12913-024-11967-0AblationCryoablationCost-effectivenessParoxysmal atrial fibrillationAntiarrhythmic drug |
| spellingShingle | Malte Kuniss Lucy Hillcoat Joe Moss Florian Straube Jason Andrade Oussama Wazni Gian Battista Chierchia Lukas Schwegmann Eleni Ismyrloglou Alicia Sale Stuart Mealing Tom Bromilow Emily Lane Damian Lewis Andreas Goette An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective BMC Health Services Research Ablation Cryoablation Cost-effectiveness Paroxysmal atrial fibrillation Antiarrhythmic drug |
| title | An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective |
| title_full | An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective |
| title_fullStr | An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective |
| title_full_unstemmed | An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective |
| title_short | An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective |
| title_sort | economic evaluation of first line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a german healthcare payer perspective |
| topic | Ablation Cryoablation Cost-effectiveness Paroxysmal atrial fibrillation Antiarrhythmic drug |
| url | https://doi.org/10.1186/s12913-024-11967-0 |
| work_keys_str_mv | AT maltekuniss aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT lucyhillcoat aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT joemoss aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT florianstraube aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT jasonandrade aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT oussamawazni aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT gianbattistachierchia aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT lukasschwegmann aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT eleniismyrloglou aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT aliciasale aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT stuartmealing aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT tombromilow aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT emilylane aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT damianlewis aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT andreasgoette aneconomicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT maltekuniss economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT lucyhillcoat economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT joemoss economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT florianstraube economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT jasonandrade economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT oussamawazni economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT gianbattistachierchia economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT lukasschwegmann economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT eleniismyrloglou economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT aliciasale economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT stuartmealing economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT tombromilow economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT emilylane economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT damianlewis economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective AT andreasgoette economicevaluationoffirstlinecryoballoonablationversusantiarrhythmicdrugtherapyforthetreatmentofparoxysmalatrialfibrillationfromagermanhealthcarepayerperspective |